Price D A, Ehrlich R M, Walfish P G
Arch Dis Child. 1981 Nov;56(11):845-51. doi: 10.1136/adc.56.11.845.
The clinical and laboratory characteristics of infants with neonatal hypothyroidism, and the age at which treatment was started are reviewed. The incidence of primary hypothyroidism was 1 in 3488 live births. Most of these cases were detected in a cord blood screening programme which was carried out between October 1973 and May 1980 in the Toronto region. Forty-eight infants with primary persistent hypothyroidism were classified by technetium scintiscanning as follows: 12 with athyrosis (non-visualised thyroid glands), 14 with ectopic thyroid glands, and 14 with goitrous thyroid glands. The remaining 8 infants comprised 4 with hypoplasia and 4 with transient hypothyroidism (2 idiopathic and 2 iodide induced). Although infants with athyrosis had a lower mean thyroxine value, their values overall were not significantly different from those of the other groups. Some infants, particularly those who were goitrous or ectopic, initially had normal thyroxine values. Skeletal maturation was more often delayed in athyrotic infants than in the ectopic or goitrous group. Radioactive iodine uptakes were appreciably higher in the goitrous group, and there was no significant difference between athyrotic and ectopic groups. The mean age at which treatment was started for all patients was 25 (range 6-120) days. The average age for starting treatment using initial thyroxine and secondary thyrotrophin testing in the initial stages of the cord blood screening was 36 days. The use of initial cord serum or dried blood thyrotrophin reduced the start of treatment to 14 days. It is concluded that: (1) It is important to determine the precise anatomical diagnosis, the biochemical severity, and the age at which treatment is started in order to assess the benefits of regional screening programmes in the detection of neonatal hypothyroidism. (2) Routine technetium scintiscanning before the start of treatment helps to determine the diagnosis. (3) Radioactive -I thyroid uptake studies are no longer routinely recommended; this is because of the radiation hazard and the lack of specificity in differentiating between the various anatomical types. (4) The feasibility of cord blood screening to detect the various causes of neonatal hypothyroidism is confirmed. (5) The time between final diagnosis and the institution of treatment can be reduced by 2 or 3 weeks if a thyrotrophin test is used initially from cord blood serum or, preferably, from dried blood spotted on filter paper; the latter is easier to post to a screening laboratory.
回顾了新生儿甲状腺功能减退症患儿的临床和实验室特征,以及开始治疗的年龄。原发性甲状腺功能减退症的发病率为每3488例活产中有1例。这些病例大多是在1973年10月至1980年5月期间在多伦多地区开展的一项脐血筛查项目中检测到的。48例原发性持续性甲状腺功能减退症患儿通过锝扫描分类如下:12例为无甲状腺(甲状腺未显影),14例为异位甲状腺,14例为甲状腺肿大。其余8例患儿包括4例发育不全和4例暂时性甲状腺功能减退症(2例特发性和2例碘诱发)。尽管无甲状腺患儿的平均甲状腺素值较低,但总体上与其他组无显著差异。一些患儿,尤其是甲状腺肿大或异位的患儿,最初甲状腺素值正常。无甲状腺患儿的骨骼成熟往往比异位或甲状腺肿大组延迟。甲状腺肿大组的放射性碘摄取明显较高,无甲状腺组和异位组之间无显著差异。所有患者开始治疗的平均年龄为25(范围6 - 120)天。在脐血筛查初始阶段,使用初始甲状腺素和继发性促甲状腺素检测开始治疗的平均年龄为36天。使用初始脐血血清或干血促甲状腺素可将治疗开始时间缩短至14天。得出以下结论:(1)为评估区域筛查项目在检测新生儿甲状腺功能减退症中的益处,确定精确的解剖诊断、生化严重程度以及开始治疗的年龄很重要。(2)治疗开始前进行常规锝扫描有助于确定诊断。(3)不再常规推荐放射性碘甲状腺摄取研究;这是因为存在辐射危害且在区分各种解剖类型方面缺乏特异性。(4)证实了脐血筛查检测新生儿甲状腺功能减退症各种病因的可行性。(5)如果最初使用脐血血清促甲状腺素检测,最好是使用滤纸上的干血斑促甲状腺素检测,最终诊断与开始治疗之间的时间可缩短2至3周;后者更容易邮寄到筛查实验室。